2023中國醫藥創新企業100強榜單發佈，四環醫藥入選第一梯級企業！
10月11日，2023中國醫藥創新企業100強榜單發佈。本次榜單是由E藥經理人以科睿唯安Derwent Innovation 專利數據及Cortellis™競爭情報和臨牀試驗數據為基礎，通過“三維度四指標”評選體系，篩選數據、整合分析而成。榜單旨在為行業挖掘創新力量，傳播創新經驗，深度剖析中國醫藥產業的創新能力和可持續性。
2018年，一項權威數據公佈，中國對全球醫藥研發的貢獻上升到4%-8%，僅次於美國、日本，進入第二梯隊，這表明中國醫藥創新已經步入黃金時代。
以此為契機，E藥經理人自2019年起，通過模型搭建、數據蒐集與整理，從醫藥創新現狀出發，以企業為主體、硬數據為依託，通過創新根基、創新過程、創新成果三個維度，以授權專利數量、專利施引總量、臨牀試驗數量和創新藥獲批與上市的數量四個指標為評價依據，每年評選出代表中國醫藥創新實力的“中國醫藥創新企業100強”。至今已有五個年頭。
創新100強公司是代表中國醫藥創新能力的第一陣營、產業的核心競爭力，也是助推中國醫藥轉型升級的中堅力量。本次四環醫藥登榜第一梯級，是對公司創新實力、技術儲備與可持續創新能力的認可，以及公司在醫藥行業發展中做出突出貢獻的肯定。
今年，四環醫藥及其附屬公司不斷傳來好消息。旗下多款產品獲批上市，臨牀研究獲得重大進展，研究結果入選國際權威學術會議。接下來，希望四環醫藥能夠持續創新、開發出更多更好的中國藥，助推醫藥行業發展壯大，服務人民健康。
關於四環醫藥
四環醫藥控股集團有限公司（0460.HK）創立於2001年，2010年在香港主板上市，是一家以創新為引領，擁有獨立領先的自主研發技術平台、具備豐富的全球化產品管線、強大的產品註冊能力、高效率及低成本的全劑型生產平台和成熟卓越銷售體系的國際化生物製藥及醫美企業，旗下擁有創新藥平台軒竹生物、糖尿病平台惠升生物、醫美平台渼顏空間，以及多家高端仿製藥企業。四環醫藥近年來持續高強度研發投入，以“堅持全速推進四環醫美及生物製藥雙輪驅動戰略”為整體戰略目標來打造中國領先醫美及生物製藥企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
